Lupin’s wholly owned subsidiary Nanomi has signed a definitive agreement for the acquisition of VISUfarma, a portfolio company of global healthcare specialist investor GHO Capital Partners LLP (GHO).

The acquisition of VISUfarma, with its broad portfolio of innovative eye health products and established commercial infrastructure, reinforces Lupin’s strategy to expand its European business and footprint and to advance the company’s global specialty franchise.

By integrating VISUfarma’s established commercial operations, Lupin aims to tap into the attractive ophthalmology market.

VISUfarma’s established European operations will provide market expansion opportunities, direct presence and further business diversification across major European countries, including Italy, the UK, Spain, Germany and France. In addition, VISUfarma’s broad portfolio of over 60 branded ophthalmology products will present growth opportunities to accelerate Lupin’s expansion into the specialty segment across regions, and is projected to drive growth in Europe as well as in other markets.

Vinita Gupta, CEO of Lupin, said, “This acquisition strengthens our commitment to delivering innovative medicines to the patients and communities we serve. Beyond being immediately accretive, it also broadens our presence in Europe and further builds our specialty franchise in ophthalmology.”

Following the integration of VISUfarma, Lupin will offer a complete portfolio of products in the areas of dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health and highly focused nutraceuticals prescribed by ophthalmologists.

Andrea Ponti, Managing Partner and Mike Turner, Partner at GHO Capital, commented, “We are pleased to have found a partner to help grow VISUfarma further and leverage its strengths to build a global ophthalmology franchise.”

Paolo Cioccetti, CEO Italy, VISUfarma, added, “As part of Lupin’s ophthalmology operations, we will build towards a global ophthalmology franchise with a commitment to advancing eye care and improving patient outcomes.”

The transaction is projected to close by the end of 2025, subject to certain closing conditions.

Headquartered in Mumbai, Lupin specialises in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Its products are distributed in over 100 markets.